Liprolog Mix25 Kwikpen (Insulin Lispro)

Insulin lispro binds to insulin receptors, quickly activating intracellular pathways that move GLUT4 transporters to the cell surface, thereby increasing glucose uptake in muscle and fat cells and suppressing hepatic glucose production, which results in a rapid decline in blood glucose after meals.

The dose of insulin lispro is individualized. A qualified prescriber determines the appropriate amount based on the patient’s blood‑glucose monitoring, carbohydrate intake, and overall treatment plan. Patients should follow the dosing instructions provided by their healthcare professional.

Safety data for insulin lispro in pregnancy and lactation are limited. It may be used when the benefits outweigh potential risks, but treatment decisions should be made by a healthcare provider familiar with the patient’s condition and obstetric history.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Insulin lispro has a rapid onset and short duration similar to other rapid‑acting analogs such as insulin aspart and insulin glulisine. Compared with regular human insulin, lispro provides faster glucose control after meals, allowing more flexible dosing and reduced post‑prandial hyperglycemia.

Store the prefilled pen at 2‑8 °C (refrigerated) and protect it from light. Do not freeze or shake the pen. Once in use, it may be kept at controlled room temperature (up to 30 °C) for a maximum of 28 days, as indicated in the product labeling.

The medication is delivered by subcutaneous injection using the Kwikpen device. Patients should select an appropriate injection site (abdomen, thigh, or upper arm), rotate sites to avoid lipodystrophy, and follow the pen’s instructions for dose setting, needle insertion and disposal.

The most serious risks include severe hypoglycemia, which can cause loss of consciousness or seizures, and allergic reactions ranging from rash to anaphylaxis. Prompt recognition and treatment of these events are essential, and patients should be educated on emergency measures.

Individuals with a known hypersensitivity to insulin lispro or any excipients in the formulation should avoid this product. It is also contraindicated in patients experiencing hypoglycemia until the condition is corrected, and caution is advised in those with severe renal or hepatic impairment.